Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma

Cha Len Lee, Grainne M. O'Kane, Warren P. Mason, Wen-Jiang Zhang, Pavlina Spiliopoulou, Aaron R. Hansen, Robert C. Grant, Jennifer J. Knox, Tracy L. Stockley, Gelareh Zadeh, Eric X. Chen

Mol Cancer Ther (2024) 23 (3): 394–399.

https://doi.org/10.1158/1535-7163.MCT-23-0460

Published: 04 March 2024

View articletitled, Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma

Journal Articles

Abstract P035: A phase 1 pharmacokinetic trial of single agent trametinib a MEK inhibitor in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI 9591)

Pei Jye Voon, Eric X. Chen, Helen X. Chen, Albert C. Lockhart, Solmaz Sahebjam, Karen Kelly, Ulka N. Vaishampayan, Vivek Subbiah, Albiruni R. Razak, Daniel J. Renouf, Sebastien J. Hotte, Arti Singh, Philippe L. Bedard, Aaron R. Hansen, Ivy S. Percy, Lisa Wang, Lee-Anne Stayner, Lillian L. Siu, Anna Spreafico

Mol Cancer Ther (2021) 20 (12_Supplement): P035.

https://doi.org/10.1158/1535-7163.TARG-21-P035

Published: 01 December 2021

View articletitled, Abstract P035: A phase 1 pharmacokinetic trial of single agent trametinib a MEK inhibitor in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI 9591)

Journal Articles

Abstract B23: Real-time dynamic assessment of RAF-signal transduction capacity as a predictive biomarker in patients with advanced neuroendocrine tumor (aNET) treated with sorafenib (S) and metronomic cyclophosphamide (mC): The SORNET study.

Miguel Quintela-Fandino, Monika Krzyzanowska, Gordon Duncan, Ashley Young, Malcolm J. Moore, Eric X. Chen, Anasthasios Stathis, Jennifer Petronis, Mandeep Grewal, Sheila Webster, Lisa Wang, Lillian L. Siu

Mol Cancer Ther (2011) 10 (11_Supplement): B23.

https://doi.org/10.1158/1535-7163.TARG-11-B23

Published: 12 November 2011

View articletitled, Abstract B23: Real-time dynamic assessment of RAF-signal transduction capacity as a predictive biomarker in patients with advanced neuroendocrine tumor (aNET) treated with sorafenib (S) and metronomic cyclophosphamide (mC): The SORNET study.

Journal Articles

Abstract A50: Biomarker analysis of PTEN, targeted oncogenic mutations, and HPV in a phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor dacomitinib (D) (PF-299804) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Lillian L. Siu, Ghassan Allo, Gregory R. Pond, Tong Zhang, James Ho, Sebastien J. Hotte, Scott A. Laurie, Simron Singh, Eric Winquist, Stephen K. L. Chia, Eric X. Chen, Kelvin K. Chan, Christine Mormont, Susan Quinn, Tao Wang, Ian Taylor, Suzanne Kamel-Reid, Ming S. Tsao, Denis Soulieres

Mol Cancer Ther (2011) 10 (11_Supplement): A50.

https://doi.org/10.1158/1535-7163.TARG-11-A50

Published: 12 November 2011

View articletitled, Abstract A50: Biomarker analysis of PTEN, targeted oncogenic mutations, and HPV in a phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor dacomitinib (D) (PF-299804) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Journal Articles

Abstract C17: A phase I study of the combination of RO4929097 (RO) and cediranib (Cd) in patients with advanced solid tumors (PJC-004/NCI 8503).

Vincent Castonguay, Philippe L. Bedard, Helen X. Chen, Percy Ivy, Amit M. Oza, Eric X. Chen, Hal W. Hirte, Angela McGarrity, Anne Laughlin, Sonya Lovell, Lisa Wang, Lillian L. Siu, Sebastien Hotte

Mol Cancer Ther (2011) 10 (11_Supplement): C17.

https://doi.org/10.1158/1535-7163.TARG-11-C17

Published: 12 November 2011

View articletitled, Abstract C17: A phase I study of the combination of RO4929097 (RO) and cediranib (Cd) in patients with advanced solid tumors (PJC-004/NCI 8503).

Journal Articles

Abstract B50: A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.

Albiruni RA Razak, Philippe L. Bedard, Benoit You, Devang Panchal, Eric X. Chen, S. Percy Ivy, Wen-Jiang Zhang, Suzanne Kamel-Reid, Nhu-An Pham, Tong Zhang, Sebastien J. Hotte, Michael Reedijk, Momiko Shimizu, Laurie Ailles, Christine Haines, Amit Oza, Ming Tsao, Lillian L. Siu

Mol Cancer Ther (2011) 10 (11_Supplement): B50.

https://doi.org/10.1158/1535-7163.TARG-11-B50

Published: 12 November 2011

View articletitled, Abstract B50: A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.

Journal Articles

Abstract C25: A phase I study evaluating the proton pump inhibitor pantoprazole (PTP) in combination with doxorubicin (DOX) for advanced cancer patients (pts).

Suzanne Richter, Ben Tran, Krupa Patel, Alberto Ocana, Lisa Wang, Christine Haines, Melanie Recel, Eric X. Chen, Ian F. Tannock, Lillian L. Siu, Philippe L. Bedard

Mol Cancer Ther (2011) 10 (11_Supplement): C25.

https://doi.org/10.1158/1535-7163.TARG-11-C25

Published: 12 November 2011

View articletitled, Abstract C25: A phase I study evaluating the proton pump inhibitor pantoprazole (PTP) in combination with doxorubicin (DOX) for advanced cancer patients (pts).

Journal Articles

Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort

Miguel Quintela-Fandino, Christophe Le Tourneau, Ignacio Duran, Eric X. Chen, Lisa Wang, Ming Tsao, Bizhan Bandarchi-Chamkhaleh, Nhu-Ann Pham, Trevor Do, Martha MacLean, Rakesh Nayyar, Michael W. Tusche, Ur Metser, John J. Wright, Tak W. Mak, Lillian L. Siu

Mol Cancer Ther (2010) 9 (3): 751–760.

https://doi.org/10.1158/1535-7163.MCT-09-0868

Published: 09 March 2010

View articletitled, Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort

Journal Articles

Abstract A55: A first‐in‐human, phase I study of an oral hedgehog pathway antagonist, BMS‐833923 (XL139), in subjects with advanced or metastatic solid tumors

Lillian L. Siu, Kyriakos P. Papadopoulos, Steven R. Alberts, Sara Taylor, Amita Patnaik, Eric X. Chen, Anthony Tolcher, Blisse Vakkalaguada, Lixin Lang, Christoph Ahlers, Kelly L. Bennett, Jan M. Van Tornout

Mol Cancer Ther (2009) 8 (12_Supplement): A55.

https://doi.org/10.1158/1535-7163.TARG-09-A55

Published: 10 December 2009

View articletitled, Abstract A55: A first‐in‐human, phase I study of an oral hedgehog pathway antagonist, BMS‐833923 (XL139), in subjects with advanced or metastatic solid tumors

Journal Articles

Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors

Lillian L. Siu, Sebastien J. Hotte, Eric X. Chen, Hal W. Hirte, Jean Powers, Lee‐Anne Stayner, Anne Iacobucci, Veronica Novotny‐Diermayr, Joy Zhu, Elizabeth A. Eisenhauer

Mol Cancer Ther (2009) 8 (12_Supplement): A185.

https://doi.org/10.1158/1535-7163.TARG-09-A185

Published: 10 December 2009

View articletitled, Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma

Abstract P035: A phase 1 pharmacokinetic trial of single agent trametinib a MEK inhibitor in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI 9591)

Abstract B23: Real-time dynamic assessment of RAF-signal transduction capacity as a predictive biomarker in patients with advanced neuroendocrine tumor (aNET) treated with sorafenib (S) and metronomic cyclophosphamide (mC): The SORNET study.

Abstract C17: A phase I study of the combination of RO4929097 (RO) and cediranib (Cd) in patients with advanced solid tumors (PJC-004/NCI 8503).

Abstract B50: A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.

Abstract C25: A phase I study evaluating the proton pump inhibitor pantoprazole (PTP) in combination with doxorubicin (DOX) for advanced cancer patients (pts).

Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort

Abstract A55: A first‐in‐human, phase I study of an oral hedgehog pathway antagonist, BMS‐833923 (XL139), in subjects with advanced or metastatic solid tumors

Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only